Literature DB >> 17961801

Implantable cardioverter defibrillator therapy in athletes.

Hein Heidbüchel1.   

Abstract

Implantable cardioverter defibrillators (ICD) prevent recurrent arrhythmic death in sudden death survivors or may prevent its development in physically active patients with an underlying risk for malignant ventricular arrhythmias. Although ICD do not substitute for the usual recommendations to refrain from intensive or competitive exercise because of an underlying arrhythmic disorder, they often provide a means for safe continuation of mild to moderate recreational sports activity. Long-term quality of life will be highly dependent on the prevention of inappropriate ICD shocks. This requires the choice of a durable lead and device system, careful programming tailored to the characteristics of the patient's physiologic and pathologic heart rhythms, preventive bradycardic medication, and guided rehabilitation with psychologic counseling.

Entities:  

Mesh:

Year:  2007        PMID: 17961801     DOI: 10.1016/j.ccl.2007.07.004

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  5 in total

1.  Syncope in the athlete.

Authors:  B P Grubb; B Karabin
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-07-28

Review 2.  Inherited primary arrhythmia disorders: cardiac channelopathies and sports activity.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; M Ben Miled; S Kachboura
Journal:  Herz       Date:  2018-05-09       Impact factor: 1.443

Review 3.  Athletes with Implantable Cardioverter Defibrillators.

Authors:  Shiva P Ponamgi; Christopher V DeSimone; Michael J Ackerman
Journal:  Clin Sports Med       Date:  2015-07       Impact factor: 2.182

4.  Atrial and ventricular lead insulation defects with resulting inappropriate shocks and end-of-life of the ICD pulse generator in a young bodybuilder with congenital long-QT-syndrome.

Authors:  Claudius Diez; Hans-Stefan Hofmann; Jochen Börgermann
Journal:  Clin Res Cardiol       Date:  2008-09-05       Impact factor: 5.460

5.  Heart and athlete.

Authors:  Mohammad Alasti; Bita Omidvar; Mohammad Hossein Jadbabaei
Journal:  J Tehran Heart Cent       Date:  2010-02-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.